文献速递肝病消化道肿瘤与早癌

PD-L1阻断释放肝细胞癌中糖酵解巨噬细胞的内在抗肿瘤特性

PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma.
PubMed 文献 · Gut · 2022-02-16

研究纳入184例未经治疗的肝细胞癌患者及Hepa1-6细胞荷瘤C57BL/6小鼠,发现PD-L1+宿主巨噬细胞呈HLA-DRhighCD86high糖酵解表型并产生抗肿瘤IL-12p70;PKM2+糖酵解巨噬细胞增多预示预后不良,阻断PD-L1可解除免疫抑制并释放其抗肿瘤特性。

要点

  • PD-L1+宿主巨噬细胞是肝细胞癌中PD-L1的主要细胞来源,呈HLA-DRhighCD86high糖酵解表型。
  • 肿瘤细胞来源纤连蛋白1经HIF-1α依赖方式触发PKM2,调控巨噬细胞抗肿瘤特性与PD-L1表达。
  • PKM2+糖酵解巨噬细胞增多预示患者预后不良,阻断PD-L1可释放其内在抗肿瘤特性。

核心结论

  • 选择性调控肝细胞癌肿瘤中糖酵解巨噬细胞的「背景」可能恢复其抗肿瘤特性,为抗癌治疗提供精准策略。

研究设计与样本

  • 共随机纳入184例未经治疗的肝细胞癌患者,C57BL/6小鼠注射Hepa1-6细胞形成自体肝癌。
  • 采用ELISpot、流式细胞术和实时PCR分析直接从肝细胞癌标本及配对血样分离或体外培养生成的PD-L1+细胞表型。
  • 采用免疫荧光和免疫组化检测石蜡包埋及福尔马林固定样本中的免疫细胞,并通过体内外研究评估代谢转换的调控机制。

主要发现

  • PD-L1+宿主巨噬细胞构成肝细胞癌肿瘤中PD-L1的主要细胞来源,呈HLA-DRhighCD86high糖酵解表型,显著产生抗肿瘤IL-12p70,并由内在糖酵解代谢极化。
  • 肿瘤细胞来源纤连蛋白1经HIF-1α依赖方式触发关键糖酵解酶PKM2,同时调控糖酵解巨噬细胞的抗肿瘤特性与炎症介导的PD-L1表达。
  • PKM2+糖酵解巨噬细胞增多预示患者预后不良,但阻断这些细胞上的PD-L1可消除PD-L1主导的免疫抑制并释放内在抗肿瘤特性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with increased PD-L1+ host cells in tumours are more potent to benefit from antiprogrammed death-1/programmed death ligand-1 (PD-L1) treatment, but the underlying mechanism is still unclear. We aim to elucidate the nature, regulation and functional relevance of PD-L1+ host cells in hepatocellular carcinoma (HCC). DESIGN: A total of untreated 184 HCC patients was enrolled randomly. C57BL/6 mice are given injection of Hepa1-6 cells to form autologous hepatoma. ELISpot, flow cytometry and real-time PCR are applied to analyse the phenotypic characteristics of PD-L1+ cells isolated directly from HCC specimens paired with blood samples or generated from ex vivo and in vitro culture systems. Immunofluorescence and immunohistochemistry are performed to detect the presence of immune cells on paraffin-embedded and formalin-fixed samples. The underlying regulatory mechanisms of metabolic switching are assessed by both in vitro and in vivo studies. RESULTS: We demonstrate that PD-L1+ host macrophages, which constructively represent the major cellular source of PD-L1 in HCC tumours, display an HLA-DRhighCD86high glycolytic phenotype, significantly produce antitumourigenic IL-12p70 and are polarised by intrinsic glycolytic metabolism. Mechanistically, a key glycolytic enzyme PKM2 triggered by hepatoma cell derived fibronectin 1, via a HIF-1α-dependent manner, concurrently controls the antitumourigenic properties and inflammation-mediated PD-L1 expression in glycolytic macrophages. Importantly, although increased PKM2+ glycolytic macrophages predict poor prognosis of patients, blocking PD-L1 on these cells eliminates PD-L1-dominant immunosuppression and liberates intrinsic antitumourigenic properties. CONCLUSIONS: Selectively modulating the 'context' of glycolytic macrophages in HCC tumours might restore their antitumourigenic properties and provide a precise strategy for anticancer therapy.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Lu LG, Zhou ZL, Wang XY, et al. PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma. Gut. 2022. PMID: 35173040. doi:10.1136/gutjnl-2021-326350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。